m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00619
 [1], [2], [3]
m6A modification hsa-miR-34a hsa-miR-34a METTL14 Methylation : m6A sites Indirect Enhancement RNA modification BCL2 BCL2 PUS1 Methylation : modification sites
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target hsa-miR-34a
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Pseudouridine
Epigenetic Regulator Pseudouridylate synthase 1 homolog (PUS1) WRITER View Details
Regulated Target Apoptosis regulator Bcl-2 (BCL2) View Details
Crosstalk Relationship m6A  →  Pseudouridine Enhancement
Crosstalk Mechanism m6A modification indirectly impacts RNA modification through downstream signaling pathways
Crosstalk Summary METTL14 interacts with hsa-miR-34a, increasing its m6A level and promoting its physical interaction with Apoptosis regulator Bcl-2 (BCL2), which was regulated by PUS1-mediated Pseudouridine modification.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Apoptosis regulator Bcl-2 (BCL2) 49 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name GDC-0199 Approved [4]
MOA Modulator
Activity Ki < 0.01 nM
External Link
CID: 49846579
TTD: D00PBX
DrugBank: DB11581
 Compound Name MCI-186 Approved [5]
Synonyms
Edarabone; Edaravone; Methylphenylpyrazolone; Monopyrazolone; Norantipyrine; Norphenazone; Phenylmethylpyrazolone; Radicut; Developer Z; Edaravone [INN]; Phenyl methyl pyrazolone; CDS1_000986; CI Developer 1; IN1263; M0687; MCI 186; Edaravone(jan); Radicut (TN); AE-641/00371017; C.I. Developer 1; Edaravone (JAN/INN); (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 1-Phenyl-3-methyl-5-pyrazolone; 1-Phenyl-3-methylpyrazolone; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; 3-Methyl-1-phenyl-2-pyrazoline-5-one; 3-Methyl-1-phenyl-5-pyrazolone; 3-Methyl-1-phenylpyrazol-5-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 5-methyl-2-phenyl-4H-pyrazol-3-one
    Click to Show/Hide
MOA Regulator (upregulator)
External Link
CID: 4021
TTD: D06DLI
DrugBank: DB12243
 Compound Name Taxol Approved [6]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
MOA Modulator
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Oblimersen Phase 3 [7]
MOA Inhibitor
External Link
CID: 118984457
TTD: D05RJP
 Compound Name RG7601 Phase 3 [4]
MOA Modulator
External Link
TTD: D0I6OI
 Compound Name Taxol/Paraplatin/Herceptin Phase 3 [8]
Synonyms
Paclitaxel/carboplatin/trastuzumab
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0J6PY
 Compound Name ABT-263 Phase 3 [9]
Synonyms
Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 0.01 nM
External Link
CID: 24978538
TTD: D06ETI
DrugBank: DB12340
 Compound Name Thymoquinone Phase 2/3 [10]
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10281
TTD: DY4OZ6
 Compound Name Gossypol Phase 2 [11]
Synonyms
303-45-7; (-)-Gossypol; 90141-22-3; (+)-Gossypol; Pogosin; Tash 1; racemic-Gossypol; (R)-(-)-Gossypol; (R)-Gossypol; (+-)-Gossypol; (+/-)-Gossypol; CCRIS 2689; NSC56817; NSC 56817; NSC 624336; BRN 1917878; CHEMBL51483; AI3-22957; 20300-26-9; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde; 2,2'-bi[8-Formyl-1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene]; 2,2'-Bis(1,6,7-trihydroxy-3-methyl-5-isopropyl-8-aldehydonaphthalene); NSC624336; Gossypol acetate
    Click to Show/Hide
MOA Regulator
Activity Ki = 170 nM
External Link
CID: 3503
TTD: D0Z0HH
DrugBank: DB13044
 Compound Name PI-88/Taxotere Phase 2 [12]
Synonyms
PI-88/docetaxel
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0K8LB
 Compound Name Obatoclax Phase 2 [13]
Synonyms
CHEMBL408194; UNII-QN4128B52A; QN4128B52A; SCHEMBL631676; SCHEMBL16340850; BDBM50376902; ZINC136873052; DB12191; NCGC00387855-01; BRD-K15600710-066-01-7
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 300 nM
External Link
CID: 11404337
TTD: D02OZK
DrugBank: DB12191
 Compound Name APG-2575 Phase 1/2 [14]
Synonyms
Bcl-2/Bcl-xl inhibitor 1; 2180923-05-9; OSL3FEZ1IF; UNII-OSL3FEZ1IF; SCHEMBL20580489; US10221174, Compound 6; BDBM361577; HY-129179; CS-0103865; (S)-N-((4-(((1,4-dioxan-2-yl)methyl)amino)-3- nitrophenyl)sulfonyl)-2-((1H-pyrrolo[2,3-b]pyridin- 5-yl)oxy)-4-(4-((6-(4-chlorophenyl)spiro[3.5]non-6- en-7-yl)methyl)piperazin-1-yl)benzamide; Benzamide, 4-(4-((6-(4-chlorophenyl)spiro(3.5)non-6-en-7-yl)methyl)-1-piperazinyl)-N-((4-(((2S)-1,4-dioxan-2-ylmethyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 137355972
TTD: D2Y7ZG
 Compound Name APG-1252 Phase 1/2 [15]
MOA Inhibitor
External Link
TTD: D4WN2M
 Compound Name AZD0466 Phase 1/2 [16]
MOA Inhibitor
External Link
TTD: DQ1P6X
 Compound Name BCL201 Phase 1 [17]
MOA Inhibitor
External Link
TTD: D0C6YQ
 Compound Name Pc4 Phase 1 [18]
Synonyms
Pc4 (topical formulation, cancer/psoriasis/dermatological disease) Fluence/CWRU/UHCMC
    Click to Show/Hide
MOA Agonist
External Link
TTD: D0L2YF
 Compound Name BGB-11417 Phase 1 [19]
MOA Inhibitor
External Link
TTD: D74BRK
 Compound Name LP-108 Phase 1 [20]
External Link
TTD: DBY42T
 Compound Name LOXO-338 Phase 1 [21]
MOA Inhibitor
External Link
TTD: DJLX87
 Compound Name VOB560 Phase 1 [22]
Synonyms
S 65487
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: DP63FS
 Compound Name AI-850 Phase 1 [23]
MOA Modulator
External Link
TTD: D03UDW
 Compound Name Irofulven/Taxotere Phase 1 [24]
Synonyms
MGI 114/docetaxel
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05CHN
 Compound Name Indole-based analog 2 Patented [25]
Synonyms
PMID27744724-Compound-16
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 7100 nM
External Link
TTD: D0C2DV
 Compound Name PMID27744724-Compound-10 Patented [25]
MOA Inhibitor
Activity Ki = 5800 nM
External Link
TTD: D0IS8R
 Compound Name PMID27744724-Compound-21 Patented [25]
MOA Inhibitor
Activity Ki = 2000 nM
External Link
TTD: D0J9FN
 Compound Name Indole-based analog 3 Patented [25]
Synonyms
PMID27744724-Compound-17
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1900 nM
External Link
TTD: D0MZ7I
 Compound Name PMID27744724-Compound-18 Patented [25]
MOA Inhibitor
Activity Ki = 33000 nM
External Link
TTD: D0TU3N
 Compound Name ABT-737 Terminated [26]
Synonyms
852808-04-9; ABT 737; ABT737; UNII-Z5NFR173NV; Z5NFR173NV; 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide; CHEMBL376408; C42H45ClN6O5S2; 4-{4-[(4'-Chlorobiphenyl-2-Yl)methyl]piperazin-1-Yl}-N-{[4-({(1r)-3-(Dimethylamino)-1-[(Phenylthio)methyl]propyl}amino)-3-Nitrophenyl]sulfonyl}benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 0.6 nM
External Link
CID: 11228183
TTD: D0L8WH
 Compound Name WL-276 Investigative [27]
MOA Modulator
External Link
TTD: D04HAA
 Compound Name N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide Investigative [28]
Synonyms
CHEMBL214965; SCHEMBL15313847
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
CID: 16090304
TTD: D04RTY
 Compound Name 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine Investigative [29]
MOA Inhibitor
Activity IC50 = 1600 nM
External Link
CID: 135468219
TTD: D06AQG
 Compound Name modified HA14-1 compounds (cancer) Investigative [30]
Synonyms
Bcl-2 inhibitor (cancer), GL Pharmaceuticals; HA14-1, GL Pharmaceuticals
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0S0YV
 Compound Name Apogossypol Investigative [31]
Synonyms
BI-79D10; BI-97C1; CNDO-103; CNDO-133
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 640 nM
External Link
CID: 454878
TTD: D0V7PX
 Compound Name 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide Investigative [28]
Synonyms
CHEMBL214839; BDBM50196033
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7000 nM
External Link
CID: 16090303
TTD: D0X0CS
 Compound Name 4,5-dibenzylbenzene-1,2-diol Investigative [32]
Synonyms
4,5-Dibenzyl-1,2-benzenediol; NSC664154; AC1L8EAW; CHEMBL481409; AC1Q79U2; SCHEMBL18604567; CTK7J8443; BDBM34138; 4,5-dibenzylbenzene-1,2-diol, 9; NSC-664154
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4700 nM
External Link
CID: 379493
TTD: D0D6BH
 Compound Name TW-37 Investigative [28]
Synonyms
877877-35-5; N-[4-(2-tert-Butylphenylsulfonyl)phenyl]-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; tw 37; CHEMBL217354; N-(4-((2-(tert-butyl)phenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxy-5-(2-isopropylbenzyl)benzamide; N-[4-[(2-tert-Butylphenyl)sulfonyl]phenyl]-2,3,4-trihydroxy-5-[(2-isopropylphenyl)methyl]benzamide; N-(4-((2-Tert-Butylphenyl)sulfonyl)phenyl)-2,3,4-trihydroxy-5-((2-isopropylphenyl)methyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 200 nM
External Link
CID: 11455910
TTD: D00LHS
 Compound Name QEDIIRNIARHLAQVGDSMDR Investigative [28]
MOA Inhibitor
External Link
CID: 77280325
TTD: D0S6IW
 Compound Name PNT-2258 Phase 2 [33]
External Link
TTD: D07ACL
 Compound Name Beclanorsen Phase 1/2 [33]
Synonyms
SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
    Click to Show/Hide
External Link
TTD: D00GAM
 Compound Name BP1002 Phase 1 [33]
External Link
TTD: DBPV74
 Compound Name G3139 + Thalidomide Investigative [33]
External Link
CID: 91865905
TTD: D00DDR
 Compound Name G3139 + Irinotecan Investigative [33]
External Link
CID: 91865905
TTD: D05IAN
 Compound Name G3139 + G-CSF Investigative [33]
External Link
CID: 91865905
TTD: D0B0HK
 Compound Name G3139 + Fludarabine Investigative [33]
External Link
CID: 91865905
TTD: D0LM3T
 Compound Name BP-100-1.02 Investigative [33]
Synonyms
Liposomal Bcl-2 (lymphoma/solid tumor), Bio-Path
    Click to Show/Hide
External Link
TTD: D0Q5NZ
 Compound Name G3139 + Paclitaxel Investigative [33]
External Link
CID: 91865905
TTD: D0S1FM
 Compound Name G3139 + Dexamethasone Investigative [33]
External Link
CID: 91865905
TTD: D0W8ZE
 Compound Name G3139 + Dacarbazine Investigative [33]
External Link
CID: 91865905
TTD: D0XU1I
 Compound Name G3139 + cytarabine (ARA-C) Investigative [33]
External Link
CID: 91865905
TTD: D0XU9F
References
Ref 1 A uniparental isodisomy event introducing homozygous pathogenic variants drives a multisystem metabolic disorder. Cold Spring Harb Mol Case Stud. 2019 Dec 13;5(6):a004457. doi: 10.1101/mcs.a004457. Print 2019 Dec.
Ref 2 N6-Methyladenosine Induced miR-34a-5p Promotes TNF-alpha-Induced Nucleus Pulposus Cell Senescence by Targeting SIRT1. Front Cell Dev Biol. 2021 Mar 5;9:642437. doi: 10.3389/fcell.2021.642437. eCollection 2021.
Ref 3 Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2. Can J Physiol Pharmacol. 2019 Oct;97(10):945-951. doi: 10.1139/cjpp-2018-0743. Epub 2019 Aug 9.
Ref 4 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
Ref 5 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 6 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
Ref 7 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 8 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. doi: 10.3816/CBC.2005.n.047.
Ref 9 Clinical pipeline report, company report or official report of Roche (2009).
Ref 10 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 11 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
Ref 12 Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-1307. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.
Ref 13 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. doi: 10.3816/CLML.2010.n.059.
Ref 14 A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344. doi: 10.3727/096504020X15825405463920. Epub 2020 Feb 24.
Ref 15 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. doi: 10.1002/cam4.3090. Epub 2020 Apr 28.
Ref 16 Design and optimisation of dendrimer-conjugated Bcl-2/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. doi: 10.1038/s42003-020-01631-8.
Ref 17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 18 Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8.
Ref 19 Clinical pipeline report, company report or official report of BeiGene.
Ref 20 National Cancer Institute Drug Dictionary (drug name LP-108).
Ref 21 ClinicalTrials.gov (NCT05024045) A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. U.S.National Institutes of Health.
Ref 22 Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287. doi: 10.3390/cells9051287.
Ref 23 Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. doi: 10.1007/s11095-004-1871-1.
Ref 24 Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. doi: 10.1002/pros.10351.
Ref 25 Mcl-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Feb;27(2):163-178. doi: 10.1080/13543776.2017.1249848. Epub 2016 Nov 17.
Ref 26 Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62.
Ref 27 WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83. doi: 10.1158/0008-5472.CAN-07-6590.
Ref 28 Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. doi: 10.1021/jm060460o.
Ref 29 Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24. doi: 10.1021/jm010016f.
Ref 30 The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24.
Ref 31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920).
Ref 32 Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906. doi: 10.1021/jm901446n.
Ref 33 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.